Ruthenium-Peptide Prodrugs for Glioblastoma Treatment
Author Information
Author(s): Zhang Liyan, Zhao Gangyin, Dalrymple Trevor, Husiev Yurii, Bronkhorst Hildert, Forn-Cuní Gabriel, Lopes-Bastos Bruno, Snaar-Jagalska Ewa, Bonnet Sylvestre
Primary Institution: Leiden Institute of Chemistry, Universiteit Leiden
Hypothesis
Can cyclic ruthenium-peptide conjugates effectively cross the blood-brain barrier and target glioblastoma upon light activation?
Conclusion
The study demonstrates that cyclic ruthenium-peptide conjugates can effectively penetrate the blood-brain barrier and exhibit significant antitumor activity against glioblastoma in zebrafish models.
Supporting Evidence
- All three compounds effectively crossed the blood-brain barrier.
- Significant antitumor activity was observed in zebrafish models.
- Light activation enhanced the efficacy of the ruthenium-peptide conjugates.
Takeaway
Scientists created special drugs that can go into the brain and fight brain tumors when exposed to light.
Methodology
The study involved synthesizing cyclic ruthenium-peptide conjugates and testing their ability to cross the blood-brain barrier and target glioblastoma in zebrafish models, both in vitro and in vivo.
Limitations
The study was conducted in zebrafish models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website